Open Outbreak

Middle East respiratory syndrome

Also known as: MERS, MERS-CoV, Middle East respiratory syndrome coronavirus

Middle East respiratory syndrome (MERS) is a respiratory illness caused by the coronavirus MERS-CoV. It was first identified in Saudi Arabia and Jordan in 2012. Dromedary camels are the main animal reservoir, and people can become infected through direct or indirect contact with them. The virus can also spread between people, especially among close contacts and in hospitals. Sustained person-to-person transmission has not been documented. Illness ranges from no symptoms to severe pneumonia and breathing failure. WHO's 2026 Qatar report puts deaths at about 37% of laboratory-confirmed cases, but this overstates the risk across all infections because mild cases can go undetected. There is no licensed MERS-specific vaccine or treatment in the WHO sources reviewed. Care addresses the illness and its complications, including breathing support when needed. Most reported human cases have occurred in Saudi Arabia. A WHO notice dated 2026-11-13 described two recovered cases in Qatar, with no secondary infections detected among their monitored contacts.

Key facts

TransmissionDirect or indirect contact with infected dromedary camels; infectious respiratory particles and direct or indirect contact between people, especially in hospitals and among close contacts. Sustained human-to-human transmission has not been documented.
Incubationunknown; the retrieved sources do not establish an incubation-period estimate. Contact monitoring for 14 days in the Qatar report is not an incubation estimate.
Case fatalityAround 37% of laboratory-confirmed cases in WHO's 2026 Qatar report. This likely overestimates mortality across all infections because mild cases may be missed. Separate treated and untreated fatality estimates are unknown.
Reproduction numberunknown; no numerical R0 or secondary attack-rate estimate was established by the retrieved literature or WHO pages.
VaccineNo MERS vaccine licensed according to the WHO fact sheet retrieved for this page.
TreatmentNo licensed MERS-specific treatment according to WHO. Clinical care addresses severity and complications; severe illness may require oxygen, ventilatory support and intensive care.
ReservoirDromedary camels are the primary reservoir and animal source of human infection.
Endemic regionsHuman cases are concentrated in the Arabian Peninsula, particularly Saudi Arabia. MERS-CoV circulates in dromedary camels across the Middle East and Africa and has also been detected in parts of South and Central Asia.

Transmission

MERS is an infection that can pass from animals to people. Dromedary camels are its primary reservoir. People can become infected through direct contact with infected camels, or indirectly through their secretions and possibly raw camel products. Between people, the virus can spread through infectious respiratory particles and direct or indirect contact. Transmission is most prominent in hospitals and among close contacts. Hospital outbreaks have included spread to health workers and between patients before the infection was recognized and precautions were taken. WHO reports no documented sustained person-to-person transmission anywhere in the world. This does not mean individual cases cannot cause clusters. Early recognition, testing and infection-control measures remain important.

Symptoms and severity

MERS can cause no symptoms, mild respiratory illness, or severe disease. Common symptoms are fever, cough and difficulty breathing. Pneumonia is frequent, but it is not present in every case. Some people also have diarrhoea. Severe illness can cause breathing failure and require intensive care or mechanical ventilation, a machine that supports breathing. Existing health problems are associated with more severe illness. WHO's 2026 Qatar report gives a fatality ratio of around 37% among laboratory-confirmed cases. That is not the chance of death for every infected person: mild infections may go undetected, making confirmed cases appear disproportionately severe. The retrieved sources do not provide separate fatality estimates with and without treatment.

Treatment and vaccines

The WHO fact sheet reviewed for this page states that no MERS-specific treatment or vaccine is licensed. Care therefore addresses the patient's illness and complications rather than relying on a licensed medicine that specifically targets MERS-CoV. Severe breathing problems may require oxygen, ventilatory support or intensive care. Both infections described in WHO's 2026 Qatar report ended in recovery; one involved severe pneumonia and required substantial breathing support. These outcomes do not establish the effectiveness of a particular treatment. Prevention remains essential, especially early testing and precautions in health-care facilities. WHO lists MERS as a priority pathogen for research and development because of its severity and the lack of licensed disease-specific countermeasures.

Where it occurs

Reported human infections are concentrated in the Arabian Peninsula, particularly Saudi Arabia. WHO says cases reported since 2020 have been sporadic and concentrated in this region. The animal reservoir has a wider distribution: MERS-CoV circulates in dromedary camels across the Middle East and Africa and has been detected in some countries in South and Central Asia. Animal circulation does not mean that every affected country has the same burden of recognized human disease. Cases outside the Middle East have usually involved people infected there before travelling elsewhere. Imported infections can lead to hospital outbreaks, as happened in the Republic of Korea in 2015. Surveillance therefore matters beyond the main reporting region.

Recent history

Open Outbreak lists 65 archived MERS events. These are archive records, not 65 necessarily separate outbreaks. Returned entries include notices from Saudi Arabia, Oman, Qatar and the United Arab Emirates, as well as reports outside the Middle East. The archive's 2025-12-24 global update lists 19 cases and four deaths for that report, not as a lifetime total. The latest WHO notice retrieved, dated 2026-11-13, describes two Qatar infections confirmed on 2026-08-05 and 2026-08-25, the country's first reported cases since 2022. Both recovered. All 99 identified contacts tested negative, and no secondary cases were detected. WHO considered the infections likely separate camel-associated events, although their precise sources remained undetermined.

What to watch

The most important warning signals are larger hospital clusters, infections among health workers, and repeated transmission between people without a clear camel exposure. Sustained community transmission would be a significant change from WHO's reported pattern. Cases in new regions also matter, especially where infection is acquired locally rather than imported through travel. Delays in diagnosis deserve attention because unrecognized cases have spread in hospitals. The Qatar report illustrates this challenge: an initial upper-airway specimen was negative before a lower-respiratory specimen confirmed infection. Countermeasure updates should distinguish research candidates from licensed vaccines or treatments. Vaccine supply and treatment resistance would become relevant monitoring issues if effective countermeasures become available; the reviewed sources establish neither a licensed product nor a resistance trend.

Related outbreaks

Updated